[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.]
Remember that British group with frontman Robert Smith? OK, that’s the mnemonic hook for our three-French-hens biotech. But first let me tease you.
If I said to you, I’m a doctor, and I’ve got The Compound, what for you The Compound be? What would it do? What would it treat? How would it fix you? What unfulfilled wishes would it address? Stop for a moment and level this hypothetical at yourself this Christmas season as a heuristic exercise. What are you struggling with? Would The Compound be something that cures and prevents all cancer? That reverses aging? That utterly clears up vascular disease? Maybe The Compound would confer on you an eye for investing so that in future you never lose?
But another definition is out there, and lurks in time and myth. It’s apparent, certainly, if you google (or go to the wikipedia entry for) nootrope. It may exist in a certain procrustean form in the Strattera and Adderall sold furtively and on the sneak in college dormitories around exam times. If a doctor offered me The Compound, what I would project onto that pregnant but implication-free tabula rasa that she’s offering is a pill that would boost intelligence….that would add brain faculties, aptitudes and IQ points. With The Compound, I could speak Russian like Nabokov himself, master Chopin’s really pianistic pieces, and pluck prime factors for large numbers out of the air. Or perhaps I could remember all the juicy quotes from all the films I love. Or could make splendid Sukothai pottery on first throw. I might do a second PhD in particle physics while mastering the violin.
Now, maybe your bladder should be empty for this next part. What if I told you that such a drug may be a reality, and that you can dabble in it in the form of a penny stock, and that it has catalysts coming, and that much rational sizing up of its investing situation argues it may be a looming ten-bagger? Would that excite you? Would that be a nice Christmas present from your pals at ...